ReviewCold Spring Harbor perspectives in medicine2019
The Impact of Next-Generation Sequencing on Cancer Genomics: From Discovery to Clinic.
Review in Cold Spring Harbor perspectives in medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed.
- Multi-Omics and Liquid Biopsy Integration for Precision Stratification of Breast Cancer.Cancers · 2026Review
- Review
- Experiences accessing and receiving tumour genetic profiling in Victoria: a consumer-led cross-sectional survey study.BMC cancer · 2026Article
- Deep learning-driven recognition of panoramic tumor microenvironment features in H&E sections and its application.Journal for immunotherapy of cancer · 2026Review
- Enhancing cancer classification accuracy with a self-attention network using panel capture sequencing data.Briefings in bioinformatics · 2026Article
- Multimodal deep learning for survival prediction and biomarker discovery in non-small cell lung cancer.BioData mining · 2026Article
- Multi-Institutional Study Evaluating the Role of Early Circulating Tumor DNA Dynamics During Treatment With Immune Checkpoint Inhibitors in Patients With Advanced-Stage Melanoma.JCO precision oncology · 2026Article
- Mutational signatures in hematological malignancies.Einstein (Sao Paulo, Brazil) · 2026Review
- Article
- Differential effects of KRAS G-domain and hypervariable region mutants on cancer phenotypes.Scientific reports · 2025Article
- Informatics at the Frontier of Cancer Research.Cancer research · 2025Review
- Validation of a Compact and Self-Contained Pyrosequencing Platform for Clinical Screening ofDiagnostics (Basel, Switzerland) · 2025Article
- Enhancing Cancer Screening and Early Diagnosis in India: Overcoming Challenges and Leveraging Emerging Technologies.Cureus · 2025Review
- Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation.Exploration of targeted anti-tumor therapy · 2025Review
- Transforming Cancer Care: Genomic Profiling, AI, and Next-Generation Drug Delivery Systems.Current genomics · 2025Review
- Advancements in pathology: Digital transformation, precision medicine, and beyond.Journal of pathology informatics · 2025Review
- Multimodal integration strategies for clinical application in oncology.Frontiers in pharmacology · 2025Review
- Next-generation sequencing guides diagnosis and treatment in a complex presentation of ALK-positive anaplastic large-cell lymphoma: a case report.Frontiers in oncology · 2025Article
- Single-Cell Transcriptomics Sheds Light on Tumor Evolution: Perspectives from City of Hope's Clinical Trial Teams.Journal of clinical medicine · 2024Article
- Nanomedicine for cancer patient-centered care.MedComm · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The application of next-generation sequencing (NGS) technology to the study of cancer genomes has been transformational. Not only has this technology revealed the genetic and epigenetic underpinnings of disease onset and progression, but also has redefined our clinical diagnosis and treatment paradigms. This rapid translation from discovery to clinical platform has occurred in the context of new pharmaceutical paradigms, enabling the use of NGS for the diagnosis and definition of therapeutic vulnerabilities of cancer. This review explores this transformation and identifies cutting-edge applications of NGS that will result in its additional utility in cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.